DAIICHI SANKYO, INC.

Datopotamab deruxtecan, a TROP2-directed ADC developed by Daiichi Sankyo and AstraZeneca, is being tested in three phase 3 trials for nonsquamous non-small cell lung cancer. The trials aim to evaluate its efficacy in combination with targeted treatments or immunotherapies, with primary endpoints focusing on progression-free survival and overall survival.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.

Three phase 3 trials initiated for datopotamab deruxtecan-based combinations in advanced nonsquamous non-small cell lung cancer patients, evaluating efficacy and safety.

American Regent launches 30 mL Epinephrine Injection, USP for treating anaphylaxis and hypotension in septic shock. Available for immediate shipment, it is supplied as a 30 mL multiple-dose vial (1 mg/mL).

The global MoCoD-A treatment market, valued at USD 25 million in 2022, is projected to reach USD 89.96 million by 2033, driven by advancements in genetic and precision medicine. Key players include BridgeBio Pharma, Origin Biosciences, and Orphatech Pharmaceuticals, with treatments like BBP-871 for MoCoD-A. The market growth emphasizes the need for continued research in rare genetic diseases.

DelveInsight's 'Duchenne Muscular Dystrophy (DMD) Pipeline Insight, 2024' analyzes over 75 pipeline drugs from 75+ companies, focusing on recent FDA, EMA, and PMDA approvals, clinical trials, emerging therapies, and key players like Roche, Santhera, and Sarepta. The report covers various stages of development, routes of administration, and mechanisms of action, offering insights into the evolving DMD therapeutics landscape.

The article discusses the importance of enabling JavaScript for optimal app performance.

Thermo Fisher's Oncomine receives FDA approval as a companion diagnostic for grade 2 IDH-mutant glioma, identifying patients eligible for Servier's Voranigo treatment. Voranigo, a once-daily IDH1/IDH2 inhibitor, is the first targeted therapy for this condition, with projected sales of $37m by 2030.

The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.

Thermo Fisher Scientific's Oncomine receives FDA approval for grade 2 IDH-mutant glioma, identifying patients eligible for Servier Pharmaceuticals' Voranigo treatment. Voranigo, a once-daily IDH1/IDH2 inhibitor, is the first targeted therapy for this condition. Oncomine, initially approved in 2017, is also used for NSCLC, CCA, MTC, and TC.